Back to GetFilings.com
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------------------------
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
January 31, 2003 0-11088
For the quarterly period ended Commission file number
ALFACELL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 22-2369085
(State or other jurisdiction of (I.R.S. Employer Identification No.)
organization)
225 Belleville Avenue, Bloomfield, New Jersey 07003
(Address of principal executive offices) (Zip Code)
(Registrant's telephone number, including area code) (973) 748-8082
NOT APPLICABLE
(Former name, former address, and former fiscal year,
if changed since last report.)
Indicate by check mark whether the registrant has (1) filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes |X| No |_|
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act) Yes |_| No |X|
The number of shares of common stock, $.001 par value, outstanding as of
March 14, 2003 was 22,982,958 shares.
ALFACELL CORPORATION
(A Development Stage Company)
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
BALANCE SHEETS
January 31, 2003 and July 31, 2002
January 31,
2003 July 31,
ASSETS (Unaudited) 2002
----------- ----
Current assets:
Cash and cash equivalents $ 18,963 $ 85,843
Other assets 12,098 45,754
------------ ------------
Total current assets 31,061 131,597
Property and equipment, net of accumulated depreciation and amortization
of $1,131,788 at January 31, 2003 and $1,120,371 at July 31, 2002 17,190 28,607
Loan receivable, related party 71,414 68,667
------------ ------------
Total assets $ 119,665 $ 228,871
============ ============
LIABILITIES AND STOCKHOLDERS' (DEFICIENCY)
Current liabilities:
Current portion of long-term debt $ 108,680 $ 8,179
Loan payable, related party 104,033 139,794
Accounts payable 599,834 796,128
Accrued expenses 1,195,334 854,278
------------ ------------
Total current liabilities 2,007,881 1,798,379
Long-term debt, less current portion, net of debt discount of $138,460 688,001 315,929
------------ ------------
Total liabilities 2,695,882 2,114,308
------------ ------------
Stockholders' (deficiency):
Preferred stock, $.001 par value
Authorized and unissued, 1,000,000 shares at January 31, 2003 and July 31, 2002 -- --
Common stock $.001 par value
Authorized 40,000,000 shares at January 31, 2003 and July 31, 2002;
Issued and outstanding, 22,872,958 at January 31, 2003 and
22,760,921 shares at July 31, 2002 22,873 22,761
Capital in excess of par value 60,030,909 59,654,479
Deficit accumulated during the development stage (62,629,999) (61,562,677)
------------ ------------
Total stockholders' (deficiency) (2,576,217) (1,885,437)
------------ ------------
Total liabilities and stockholders' (deficiency) $ 119,665 $ 228,871
============ ============
See accompanying notes to financial statements.
- 2 -
ALFACELL CORPORATION
(A Development Stage Company)
STATEMENTS OF OPERATIONS
Three months and six months ended January 31, 2003 and 2002,
and the Period from August 24, 1981
(Date of Inception) to January 31, 2003
(Unaudited)
Three Months Ended Six Months Ended August 24, 1981
January 31, January 31, (Date of
------------ ----------- Inception) to
2003 2002 2003 2002 January 31, 2003
---- ---- ---- ---- ----------------
Revenue:
Sales $ -- $ -- $ -- $ -- $ 553,489
Investment income 120 136 234 157 1,377,357
Other income -- -- 30,000 -- 90,103
----------- ----------- ----------- ----------- ------------
Total revenue 120 136 30,234 157 2,020,949
----------- ----------- ----------- ----------- ------------
Costs and expenses:
Cost of sales -- -- -- -- 336,495
Research and development 379,866 506,458 799,370 1,007,981 40,701,343
General and administrative 152,320 188,189 288,076 383,614 21,951,522
Interest:
Related parties, net 1,286 -- 1,286 -- 1,148,833
Others 204,056 3,363 238,284 37,518 2,303,196
----------- ----------- ----------- ----------- ------------
Total costs and expenses 737,528 698,010 1,327,016 1,429,113 66,441,389
----------- ----------- ----------- ----------- ------------
Loss before state tax benefit (737,408) (697,874) (1,296,782) (1,428,956) (64,420,440)
State tax benefit -- -- 229,459 353,730 1,790,440
----------- ----------- ----------- ----------- ------------
Net loss $ (737,408) $ (697,874) $(1,067,323) $(1,075,226) $(62,630,000)
=========== =========== =========== =========== ============
Loss per basic common share $ (.03) $ (.03) $ (.05) $ (.05)
=========== =========== =========== ===========
Weighted average number of shares
outstanding 22,872,958 20,581,938 22,830,115 20,326,920
=========== =========== =========== ===========
See accompanying notes to financial statements.
- 3 -
ALFACELL CORPORATION
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
Six months ended January 31, 2003 and 2002,
and the Period from August 24, 1981
(Date of Inception) to January 31, 2003
(Unaudited)
Six Months Ended August 24, 1981
January 31, (Date of Inception)
----------- to
2003 2002 January 31, 2003
---- ---- ----------------
Cash flows from operating activities:
Net loss $(1,067,323) $(1,075,226) $(62,630,000)
Adjustments to reconcile net loss to
net cash used in operating activities:
Gain on sale of marketable securities -- -- (25,963)
Depreciation and amortization 11,417 24,080 1,542,823
Loss on disposal of property and equipment -- -- 18,926
Noncash operating expenses 14,275 107,315 6,046,328
Charge for beneficial conversion rights 200,487 -- 200,487
Amortization of debt discount 7,626 -- 7,626
Amortization of deferred compensation -- -- 11,442,000
Amortization of organization costs -- -- 4,590
Changes in assets and liabilities:
Decrease (increase) other current assets 33,656 21,439 (71,965)
(Increase) Decrease in other assets (2,747) (17,927) 24,637
Increase in interest payable-related party -- -- 744,539
(Decrease) increase in accounts payable (186,294) 329,087 970,070
Increase in accrued payroll and expenses,
related parties -- -- 2,348,145
Increase in accrued expenses 341,056 39,174 1,736,847
----------- ----------- ------------
Net cash used in operating activities (647,847) (572,058) (37,640,910)
----------- ----------- ------------
Cash flows from investing activities:
Purchase of marketable equity securities -- -- (290,420)
Proceeds from sale of marketable equity
securities -- -- 316,383
Purchase of property and equipment -- -- (1,406,836)
Patent costs -- -- (97,841)
----------- ----------- ------------
Net cash used in investing activities -- -- (1,478,714)
----------- ----------- ------------
(continued)
See accompanying notes to financial statements.
- 4 -
ALFACELL CORPORATION
(A Development Stage Company)
STATEMENTS OF CASH FLOWS, Continued
Six months ended January 31, 2003 and 2002,
and the Period from August 24, 1981
(Date of Inception) to January 31, 2003
(Unaudited)
Six Months Ended August 24, 1981
January 31, (Date of Inception)
----------- to
2003 2002 January 31, 2003
---- ---- ----------------
Cash flows from financing activities:
Proceeds from short-term borrowings $ 25,000 $ - $ 874,500
Payment of short-term borrowings (25,000) (5,000) (653,500)
(Decrease) increase in loans payable - related party, net (35,761) 135,465 2,732,901
Proceeds from bank debt and other long-term debt, net of
deferred issuance costs 615,000 -- 3,367,460
Reduction of long-term debt (3,965) (2,885) (2,946,425)
Proceeds from issuance of common stock, net 5,693 414,180 29,366,404
Proceeds from exercise of stock options and warrants, net -- -- 5,683,254
Proceeds from issuance of convertible debentures, related party -- -- 297,000
Proceeds from issuance of convertible debentures, unrelated party -- -- 416,993
----------- ----------- ------------
Net cash provided by financing activities 580,967 541,760 39,138,587
----------- ----------- ------------
Net (decrease) increase in cash and cash equivalents (66,880) (30,298) 18,963
Cash and cash equivalents at beginning of period 85,843 44,781 --
----------- ----------- ------------
Cash and cash equivalents at end of period $ 18,963 $ 14,483 $ 18,963
=========== =========== ============
Supplemental disclosure of cash flow information - interest paid $ 3,846 $ 5,278 $ 1,686,487
=========== =========== ============
Noncash financing activities:
Issuance of convertible subordinated debenture for loan payable
to officer $ - $ - $ 2,725,000
=========== =========== ============
Issuance of common stock upon the conversion of convertible
subordinated debentures, related party $ - $ - $ 3,242,000
=========== =========== ============
Conversion of short-term borrowings to common stock $ - $ - $ 226,000
=========== =========== ============
Conversion of accrued interest, payroll and expenses by related
parties to stock options $ - $ - $ 3,194,969
=========== =========== ============
Repurchase of stock options from related party $ - $ - $ (198,417)
=========== =========== ============
Conversion of accrued interest to stock options $ - $ - $ 142,441
=========== =========== ============
Conversion of accounts payable to common stock $ 10,000 $ 50,000 $ 370,326
=========== =========== ============
Conversion of notes payable, bank and accrued interest
to long-term debt $ - $ - $ 1,699,072
=========== =========== ============
Conversion of loans and interest payable, related party and
accrued payroll and expenses, related parties to long-term
accrued payroll and other, related party $ - $ - $ 1,863,514
=========== =========== ============
Issuance of common stock upon the conversion of convertible
subordinated debentures, other $ - $ 64,993 $ 191,993
=========== =========== ============
Issuance of common stock for services rendered $ - $ - $ 2,460
=========== =========== ============
Issuance of warrants with notes payable $ 146,086 $ - $ 146,086
=========== =========== ============
See accompanying notes to financial statements.
- 5 -
ALFACELL CORPORATION
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
(Unaudited)
1. ORGANIZATION AND BASIS OF PRESENTATION
In the opinion of management, the accompanying unaudited financial
statements contain all adjustments (consisting of normal recurring accruals)
necessary to present fairly the Company's financial position as of January 31,
2003 and its results of operations and cash flows for the three and/or six month
periods ended January 31, 2003 and 2002 and the period from August 24, 1981
(date of inception) to January 31, 2003. The results of operations for the six
months ended January 31, 2003 are not necessarily indicative of the results to
be expected for the full year.
The Company is a development stage company as defined in the Financial
Accounting Standards Board's Statement of Financial Accounting Standards No. 7.
The Company is devoting substantially all of its present efforts to establishing
a new business. Its planned principal operations have not commenced and,
accordingly, no significant revenue has been derived therefrom.
The Company has reported net losses since its inception. Also, the Company
has limited liquid resources. The report of the Company's former independent
accountants on the Company's July 31, 2002 financial statements included an
explanatory paragraph which states that the Company's recurring losses, working
capital deficit and limited liquid resources raise substantial doubt about the
Company's ability to continue as a going concern. The financial statements at
July 31, 2002 and January 31, 2003 do not include any adjustments that might
result from the outcome of this uncertainty.
The Company's continued operations will depend on its ability to raise
additional funds through various potential sources such as equity and debt
financing, collaborative agreements, strategic alliances, sale of tax benefits,
revenues from the commercial sale of ONCONASE(R), licensing of its proprietary
RNase technology and its ability to realize the full potential of its technology
and its drug candidates via out-licensing agreements with other companies. Such
additional funds may not become available as needed or be available on
acceptable terms. To date, a significant portion of the Company's financing has
been through private placements of common stock and warrants, the issuance of
common stock for stock options and warrants exercised and for services rendered,
debt financing and financing provided by the Company's Chief Executive Officer.
Additionally, the Company has raised capital through the sale of its tax
benefits. Until and unless the Company's operations generate significant
revenues, the Company will attempt to continue to fund its operations from cash
on hand and through the sources of capital previously described. From August 1,
2002 through February 27, 2003, the Company received gross proceeds of
approximately $981,000 from long-term and short-term borrowings from unrelated
parties, the private placement of common stock and warrants and other income. No
assurances can be provided that the additional capital will be sufficient to
meet the Company's needs.
2. LOSS PER COMMON SHARE
"Basic" loss per common share equals net loss divided by weighted average
common shares outstanding during the period. "Diluted" loss per common share
equals net income divided by the sum of weighted average common shares
outstanding during the period plus the effect of potentially dilutive
securities. The
- 6 -
ALFACELL CORPORATION
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS, Continued
Unaudited
2. LOSS PER COMMON SHARE, Continued
Company's Basic and Diluted per share amounts are the same since the assumed
exercise of stock options and warrants are all anti-dilutive. The amount of
options and warrants excluded from the calculation was 10,139,294 and 7,802,895
at January 31, 2003 and 2002, respectively.
3. RELATED PARTY INSTRUMENTS
The Company's CEO, Kuslima Shogen, has made loans to the Company repayable
upon demand bearing interest at 8% per annum. As of January 31, 2003, the
Company owes Ms. Shogen $104,033 classified as a current liability included in
Loan payable, related party. Amounts due from Ms. Shogen totaling $71,414 are
classified as a long term asset in Loan receivable, related party as the Company
does not expect repayment of these amounts within one year. The Company earns
interest at a rate of 8% per annum.
4. ACCOUNTING FOR WARRANTS
The Company accounts for the intrinsic value of beneficial conversion
rights arising from the issuance of convertible debt instruments with
nondetachable conversion rights that are in-the money at the commitment date
pursuant to the consensuses for EITF Issue No. 98-5 and EITF Issue No. 00-27.
Such value is allocated to additional paid-in capital and the resulting debt
discount is charged to interest expense using the effective yield method over
the period to the debt instrument's earliest conversion date. Such value is
determined after first allocating an appropriate portion of the proceeds
received to warrants or any other detachable instruments included in the
exchange.
5. LONG TERM DEBT, NOTES PAYABLE
From August 2002 through January 2003, the Company issued 8% convertible
notes payable to unrelated parties with principal balances in an aggregate total
of $615,000. These notes payable are scheduled to mature on various dates from
April 2004 through May 2005. Additionally, with the issuance of the notes
payable, the Company issued to unrelated parties warrants to purchase an
aggregate of 515,000 shares of the Company's common stock expiring five years
from the date of issuance at an exercise price of $0.60 per share. In addition,
the Company will issue on the due date of the notes payable warrants to purchase
an aggregate of 715,000 shares of the Company's common stock expiring five years
from the date of issuance at per share exercise prices of $1.00 and $1.10. The
Company valued these warrants in an aggregate of $146,086 based on the fair
value determined by using the Black-Scholes method. At the issuance dates of the
notes payable, the fair market values of the Company's shares exceeded the
effective conversion prices. Accordingly, the Company initially increased
additional paid-in capital by $146,086 for the fair value of the warrants and
reduced the carrying value of the notes payable for the same amount for the debt
discount attributable to the fair value of the warrants. The Company is
amortizing the debt discount over the terms of the notes payable.
- 7 -
ALFACELL CORPORATION
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS, Continued
Unaudited
5. LONG TERM DEBT, NOTES PAYABLE, Continued
Pursuant to the applicable guidance in the consensus for EITF Issue No.
00-27, which became effective on November 16, 2000, the Company valued the
beneficial conversion feature using the effective conversion price. Accordingly,
the Company first allocated $146,086 to the detachable warrants and decreased
the carrying value of the notes payable. Based on the effective conversion
prices, the Company recorded a beneficial conversion charge of $200,487 which
was charged to interest expense in the Company's statement of operations for the
three and six months ended January 31, 2003 immediately since the notes payable
are immediately convertible at the option of the holder.
6. CAPITAL STOCK
In September 2002, the Company issued 40,000 shares of common stock upon
the exercise of warrants by an unrelated party, which resulted in gross proceeds
of $20,000 to the Company.
In October 2002, the Company issued 37,037 shares of common stock in
settlement of accounts payable in the amount of $10,000. The settled accounts
payable amount was credited to equity as the value of the common stock.
In October 2002, the Company sold 35,000 shares of common stock to a
private investor resulting in proceeds of $7,000 to the Company. In addition,
the private investor was granted five-year warrants to purchase 35,000 shares of
common stock at an exercise price of $1.00 per share.
In October 2002, the Company issued five-year stock options to purchase
25,000 shares of common stock to an unrelated party as an incentive for lending
the Company an aggregate of $25,000, of which, $5,000 was repaid during the
quarter. The stock options vested immediately and have an exercise price of
$0.23 per share. The total non-cash interest expense recorded for these stock
options was $2,503, based upon the fair value of such options on the date of
issuance, as estimated by the Black-Scholes options-pricing model.
During the period ended January 31, 2003, the Company incurred an
aggregate $21,307 of expenses relating to the registration of shares issued in
various private placements.
7. SALE OF NET OPERATING LOSSES
New Jersey has enacted legislation permitting certain corporations located
in New Jersey to sell state tax loss carryforwards and state research and
development credits, or tax benefits. For the state fiscal year 2003 (July 1,
2002 to June 30, 2003), the Company has approximately $1,372,000 total available
tax benefits of which approximately $273,000 was allocated to be sold between
July 1, 2002 and June 30, 2003. In December 2002, the Company received
approximately $229,000 from the sale of its allocated tax benefits which was
recognized as a tax benefit for the six months ended January 31, 2003. In
December 2001, the Company received approximately $354,000 from the sale of its
allocated tax benefits which was recognized as a tax benefit for the fiscal year
ended July 31, 2002. The Company
- 8 -
ALFACELL CORPORATION
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS, Continued
Unaudited
7. SALE OF NET OPERATING LOSSES, Continued
will attempt to sell the remaining balance of its tax benefits in the amount of
approximately $1,099,000 between July 1, 2003 and June 30, 2004, subject to all
existing laws of the State of New Jersey. However, there is no assurance that
the Company will be able to find a buyer for its tax benefits or that such funds
will be available in a timely manner.
8. ACCRUED EXPENSES
Included in accrued expenses as of January 31, 2003 is $690,400 of unpaid
payroll and payroll taxes. The Company is currently negotiating a payment plan
with the taxing authorities for the payment of payroll taxes with interest and
penalties, to be determined. The Company believes that any interest and
penalties assessed will not have a material adverse effect on the Company's
financial position, results of operations, or cash flows.
9. SUBSEQUENT EVENTS
In February 2003, the Company issued an aggregate of 110,000 shares of
common stock to private investors resulting in proceeds of $55,000 to the
Company. In addition, the private investors were granted five-year warrants to
purchase 110,000 shares of common stock at an exercise price of $1.25 per share.
- 9 -
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations.
Information contained herein contains, in addition to historical
information, forward-looking statements that involve risks and uncertainties.
All statements, other than statements of historical fact, regarding our
financial position, potential, business strategy, plans and objectives for
future operations are "forward-looking statements." These statements are
commonly identified by the use of forward-looking terms and phrases as
"anticipates," "believes," "estimates," "expects," "intends," "may," "seeks,"
"should," or "will' or the negative thereof or other variations thereon or
comparable terminology, or by discussions of strategy. We cannot be sure that
the future results covered by these forward-looking statements will be achieved.
The matters set forth in Exhibit 99.1 to our annual report on Form 10-K for the
fiscal year ended July 31, 2002 which is incorporated herein by reference,
constitute cautionary statements identifying important factors with respect to
these forward-looking statements, including certain risks and uncertainties,
that could cause actual results to vary significantly from the future results
indicated in these forward-looking statements. Other factors could also cause
actual results to differ significantly from the future results indicated in
these forward-looking statements.
Results of Operations
Three and six month periods ended January 31, 2003 and 2002
Revenues. We are a development stage company as defined in the Financial
Accounting Standards Board's Statement of Financial Accounting Standards No. 7.
We are devoting substantially all of our present efforts to establishing a new
business and developing new drug products. Our planned principal operations of
marketing and/or licensing of new drugs have not commenced and, accordingly, we
have not derived any significant revenue from these operations. We focus most of
our productive and financial resources on the development of ONCONASE(R) and as
such we have not had any sales in the three and six month periods ended January
31, 2003 and 2002. For the six months ended January 31, 2003, our other income
was $30,200.
Research and Development. Research and development expense for the three
months ended January 31, 2003 was $380,000 compared to $506,000 for the same
period last year, a decrease of $126,000, or 25%. This decrease was primarily
due to a decrease in costs related to our Phase III clinical trial for malignant
mesothelioma, decrease in personnel costs, decrease in regulatory consulting
costs and reduction of a non-cash expense related to stock options issued for
consulting services. These decreases were partially offset by an increase in
costs related to patent and trademark applications/renewals for ONCONASE(R).
Research and development expense for the six months ended January 31, 2003
was $799,000 compared to $1,008,000 for the same period last year, a decrease of
$209,000, or 21%. This decrease was primarily due to a decrease in costs related
to our Phase III clinical trial for malignant mesothelioma, decrease in
regulatory consulting costs, decrease in personnel costs and reduction of a
non-cash expense related to stock options issued for consulting services.
General and Administrative. General and administrative expense for the
three months ended January 31, 2003 was $152,000 compared to $188,000 for the
same period last year, a decrease of $36,000, or 19%. This decrease was
primarily due to decreases in legal and public relations expenses and a
reduction of a non-cash expense related to stock options issued for consulting
services.
General and administrative expense for the six months ended January 31,
2003 was $288,000 compared to $383,000 for the same period last year, a decrease
of $95,000, or 25%. This decrease was primarily due to decreases in public
relations and legal expenses and a reduction of a non-cash expense related to
stock options issued for consulting services.
Interest. Interest expense for the three months ended January 31, 2003 was
$204,000 compared to $3,000 for the same period last year, an increase of
$201,000. Interest expense for the six months ended January 31, 2003 was
$238,000 compared to $38,000 for the same period last year, an increase of
$200,000. These increases were primarily due to the interest expense on the
beneficial conversion feature of the notes payable issued to unrelated parties
and its related warrants. The interest expense was based on the fair value of
the warrants using the Black-Scholes method, amortized over the life of the
notes payable.
Income Taxes. New Jersey has enacted legislation permitting certain
corporations located in New Jersey to sell state tax loss carryforwards and
state research and development credits or tax benefits. For the state fiscal
year 2003 (July 1, 2002 to June 30, 2003), we have approximately $1,372,000
total available tax benefits of which approximately $273,000 was allocated to be
sold between July 1, 2002 and June 30, 2003. In December 2002, we received
approximately $229,000 from the sale of the allocated tax benefits which was
recognized as a tax benefit for the six months ended January 31, 2003. In
December 2001, we received approximately $354,000 from the sale of the allocated
tax benefits which was recognized as a tax benefit for the fiscal year ended
July 31, 2002. We will attempt to sell the remaining balance of our tax benefits
in the amount of approximately $1,099,000 between July 1, 2003 and June 30,
2004, subject to all existing laws of the State of New Jersey. However, we
cannot assure you that we will be able to find a buyer for our tax benefits or
that such funds will be available in a timely manner.
Net Loss. We have incurred net losses during each year since our
inception. The net loss for the three months ended January 31, 2003 was $737,000
as compared to $698,000 for the same period last year, a decrease of $39,000.
The net loss for the six months ended January 31, 2003 was $1,067,000 as
compared to $1,075,000 for the same period last year, a decrease of $8,000. The
cumulative loss from the date of inception, August 24, 1981 to January 31, 2003,
amounted to $62,630,000. Such losses are attributable to the fact that we are
still in the development stage and accordingly have not derived sufficient
revenues from operations to offset the development stage expenses.
Liquidity and Capital Resources
- 10 -
We have financed our operations since inception primarily through equity
and debt financing, research product sales and interest income. During the six
months ended January 31, 2003, we had a net decrease in cash and cash
equivalents of $67,000, which resulted primarily from net cash used in operating
activities of $648,000, offset by net cash provided by financing activities of
$581,000, primarily from the proceeds from long-term borrowings. Total cash
resources as of January 31, 2003 were $19,000 compared to $86,000 at July 31,
2002.
Our current liabilities as of January 31, 2003 were $2,008,000 compared to
$1,798,000 at July 31, 2002, an increase of $210,000. The increase was primarily
due to the increased accrued expenses and current portion of long-term notes
payable. As of January 31, 2003 our current liabilities exceeded our current
assets and we had a working capital deficit of $1,977,000.
Our continued operations will depend on our ability to raise additional
funds through various potential sources such as equity and debt financing,
collaborative agreements, strategic alliances, sale of tax benefits, revenues
from the commercial sale of ONCONASE(R), licensing of our proprietary RNase
technology and our ability to realize the full potential of our technology and
our drug candidates via out-licensing agreements with other companies. Such
additional funds may not become available as we need them or be available on
acceptable terms. To date, a significant portion of our financing has been
through private placements of common stock and warrants, the issuance of common
stock for stock options and warrants exercised and for services rendered, debt
financing and financing provided by our Chief Executive Officer. Additionally,
we have raised capital through the sale of our tax benefits. Until and unless
our operations generate significant revenues, we will attempt to continue to
fund operations from the sources of capital previously described. However, there
can be no assurance that we will be able to raise the capital needed. After
taking into account the net proceeds we received from the sale of our tax
benefits in December 2002, we believe that our cash and cash equivalents as of
January 31, 2003 will be sufficient to meet our anticipated cash needs through
January 31, 2004. We are continuing our fund raising efforts and anticipate
securing required financing in the second calendar quarter of 2003. The report
of our former independent auditors on our July 31, 2002 financial statements
included an explanatory paragraph which states that our recurring losses,
working capital deficit and limited liquid resources raise substantial doubt
about our ability to continue as a going concern. As of January 31, 2003, we
continued to incur losses, had a working capital deficiency and limited liquid
resources which raise substantial doubt about the Company's ability to continue
as a going concern. Our financial statements at January 31, 2003 and July 31,
2002 do not include any adjustments that might result from the outcome of this
uncertainty.
We will continue to incur costs in conjunction with our U.S. and foreign
registrations for marketing approval of ONCONASE(R). We are currently in
discussions with several potential strategic alliance partners, including major
international biopharmaceutical companies, to further the development and
marketing of ONCONASE(R) and other related products in our pipeline. However, we
cannot be sure that any such alliances will materialize.
New Jersey has enacted legislation permitting certain corporations located
in New Jersey to sell state tax loss carryforwards and state research and
development credits or tax benefits. For the state fiscal year 2003 (July 1,
2002 to June 30, 2003), we have approximately $1,372,000 total available tax
benefits of which approximately $273,000 was allocated to be sold between July
1, 2002 and June 30, 2003. In December 2002, we received approximately $229,000
from the sale of the allocated tax benefits which was recognized as a tax
benefit for the six months ended January 31, 2003. In December 2001, we received
approximately $354,000 from the sale of the allocated tax benefits which was
recognized as a tax benefit for the fiscal year ended July 31, 2002. We will
attempt to sell the remaining balance of our tax benefits in the amount of
approximately $1,099,000 between July 1, 2003 and June 30,
- 11 -
2004, subject to all existing laws of the State of New Jersey. However, we
cannot assure you that we will be able to find a buyer for our tax benefits or
that such funds will be available in a timely manner.
Our common stock was delisted from The Nasdaq SmallCap Market effective at
the close of business April 27, 1999 for failing to meet the minimum bid price
requirements set forth in the NASD Marketplace Rules. As of April 28, 1999, our
common stock trades on the OTC Bulletin Board under the symbol "ACEL.OB".
Delisting of our common stock from Nasdaq could have a material adverse effect
on our ability to raise additional capital, our stockholders' liquidity and the
price of our common stock.
The market price of our common stock is volatile, and the price of the
stock could be dramatically affected one way or another depending on numerous
factors. The market price of our common stock could also be materially affected
by the marketing approval or lack of approval of ONCONASE(R).
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Not applicable.
Item 4. Controls And Procedures.
(a) Evaluation of disclosure controls and procedures.
Under the supervision and with the participation of our management,
including our Chief Executive Officer and acting Chief Financial Officer, we
evaluated the effectiveness of the design and operation of our disclosure
controls and procedures as of March 14, 2003, the evaluation date. Based upon
the evaluation, the Chief Executive Officer and acting Chief Financial Officer
concluded that, as of the evaluation date, our disclosure controls and
procedures are effective in timely alerting her to the material information
relating to us required to be included in our periodic SEC filings.
(b) Changes in internal controls.
There were no significant changes made in our internal controls during the
period covered by this report or, to our knowledge, in other factors that could
significantly affect these controls subsequent to the date of their evaluation.
PART II. OTHER INFORMATION
Item 2. Changes in Securities and Use of Proceeds
(c) Recent Sales of Unregistered Securities
In November 2002, we issued a $200,000 8% note payable to an unrelated
party, which will become due in May 2005. In consideration for the loan, we
issued warrants to purchase 200,000 shares of common stock expiring in five
years at an exercise price of $0.60 per share. In addition, we will issue on the
due date of the note warrants to purchase 200,000 shares of common stock at an
exercise price of $1.00 per share, expiring five years from the date of
issuance. Additionally, the unrelated party can convert the note into our common
stock at a conversion rate of $0.20 per share. This transaction was exempt from
registration under Section 4(2) of the Securities Act of 1933, as amended.
In December 2002, we issued a $65,000 8% note payable to an unrelated
party, which will become
- 12 -
due in June 2004. In consideration for the loan, we issued warrants to purchase
65,000 shares of common stock expiring in five years at an exercise price of
$0.60 per share. In addition, we will issue on the due date of the note warrants
to purchase 65,000 shares of common stock at an exercise price of $1.00 per
share, expiring five years from the date of issuance. Additionally, the
unrelated party can convert the note into our common stock at a conversion rate
of $0.35 per share. This transaction was exempt from registration under Section
4(2) of the Securities Act of 1933, as amended.
In February 2003, we completed a private placement resulting in the
issuance of an aggregate of 110,000 shares of restricted common stock and
five-year warrants to purchase 110,000 shares of common stock at an exercise
price of $1.25 per share. We received $55,000 from such private placement. This
transaction was exempt from registration under Section 4(2) of the Securities
Act of 1933, as amended.
The net proceeds from the above mentioned transactions will be used for
general corporate purposes.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits (numbered in accordance with Item 601 of Regulation S-K).
Exhibit No. or
Exhibit Incorporation by
No. Item Title Reference
--- ---------- ---------
3.1 Certificate of Incorporation *
3.2 By-Laws *
3.3 Amendment to Certificate of Incorporation #
3.4 Amendment to Certificate of Incorporation +++
4.1 Form of Convertible Debenture **
10.1 Form of Stock and Warrant Purchase Agreements used in private placements
completed April 1996 and June 1996 ##
10.2 Lease Agreement - 225 Belleville Avenue, Bloomfield, New Jersey ###
10.3 Form of Stock Purchase Agreement and Certificate used in connection with various
private placements ***
10.3 Form of Stock and Warrant Purchase Agreement and Warrant Agreement used in
10.4 Private Placement completed on March 21, 1994 ***
10.5 The Company's 1993 Stock Option Plan and Form of Option Agreement *****
10.6 Debt Conversion Agreement dated March 30, 1994 with Kuslima Shogen ****
10.7 Accrued Salary Conversion Agreement dated March 30, 1994 with Kuslima Shogen ****
10.8 Accrued Salary Conversion Agreement dated March 30, 1994 with
Stanislaw Mikulski ****
10.9 Option Agreement dated March 30, 1994 with Kuslima Shogen ****
10.10 Amendment No. 1 dated June 20, 1994 to Option Agreement dated March 30, 1994 with
Kuslima Shogen ****
10.11 Form of Amendment No. 1 dated June 20, 1994 to Option Agreement dated March 30,
1994 with Kuslima Shogen *****
10.12 Form of Amendment No. 1 dated June 20, 1994 to Option Agreement dated March 30,
1994 with Stanislaw Mikulski *****
10.13 Form of Stock and Warrant Purchase Agreement and Warrant Agreement used in
Private Placement completed on September 13, 1994 +
10.14 Form of Subscription Agreements and Warrant Agreement used in Private Placements
closed in October 1994 and September 1995 #
10.15 1997 Stock Option Plan ###
10.16 Separation Agreement with Michael C. Lowe dated as of October 9, 1997 ++
10.17 Form of Subscription Agreement and Warrant Agreement used in Private Placement
completed on February 20, 1998 +++
10.18 Form of Warrant Agreement issued to the Placement Agent in connection with the
Private Placement completed on February 20, 1998 +++
10.19 Placement Agent Agreement dated December 15, 1997 +++
10.20 Separation Agreement with Gail Fraser dated August 31, 1999 ####
10.21 Form of Subscription Agreement and Warrant Agreement used in the February 2000
Private Placement ++++
10.22 Form of Subscription Agreement and Warrant Agreement used in the August and
September 2000 Private Placement +++++
10.23 Form of Subscription Agreement and Warrant Agreement used in the
- 13 -
Exhibit No. or
Exhibit Incorporation by
No. Item Title Reference
--- ---------- ---------
April 2001 Private Placements ^
10.24 Form of Convertible Note entered into in April 2001 ^
10.25 Form of Subscription Agreement and Warrant Agreement used in the July 2001
Private Placements ^
10.26 Form of Subscription Agreement and Warrant Agreement used in the August and
October 2001 Private Placements ^
10.27 Form of Subscription Agreement and Warrant Agreement used in the September 2001,
November 2001 and January 2002 Private Placements ^
10.28 Warrant issued in the February 2002 Private Placement ^
10.29 Form of Subscription Agreement and Warrant Agreement used in the March 2002 and
April 2002 Private Placements ^^
10.30 Form of Subscription Agreement and Warrant Agreement used in the June 2002 and
October 2002 Private Placements ^
10.31 Form of Note Payable and Warrant Certificate entered into April, June, July,
September, November and December 2002 ^
99.1 Factors to Consider in Connection with Forward-Looking Statements ^^^
99.2 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002 #####
99.3 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002 #####
* Previously filed as exhibit to the Company's Registration Statement on
Form S-18 (File No. 2-79975-NY) and incorporated herein by reference
thereto.
** Previously filed as exhibits to the Company's Annual Report on Form 10-K
for the year ended July 31, 1993 and incorporated herein by reference
thereto.
*** Previously filed as exhibits to the Company's Quarterly Report on Form
10-QSB for the quarter ended January 31, 1994 and incorporated herein by
reference thereto.
**** Previously filed as exhibits to the Company's Quarterly Report on Form
10-QSB for the quarter ended April 30, 1994 and incorporated herein by
reference thereto.
***** Previously filed as exhibits to the Company's Registration Statement Form
SB-2 (File No. 33-76950) and incorporated herein by reference thereto.
+ Previously filed as exhibits to the Company's Registration Statement on
Form SB-2 (File No. 33-83072) and incorporated herein by reference
thereto.
++ Previously filed as exhibits to the Company's Quarterly Report on Form
10-Q for the quarter ended October 31, 1997 and incorporated herein by
reference thereto.
+++ Previously filed as exhibits to the Company's Quarterly Report on Form
10-Q for the quarter ended January 31, 1998 and incorporated herein by
reference thereto.
++++ Previously filed as exhibits to the Company's Annual Report on Form 10-K
for the year ended July 31, 2000 and incorporated herein by reference
thereto.
- 14 -
+++++ Previously filed as exhibits to the Company's Quarterly Report on Form
10-Q for the quarter ended October 31, 2000 and incorporated herein by
reference thereto.
^ Previously filed as exhibits to the Company's Registration Statement on
Form S-1 (File No. 333-38136) and incorporated herein by reference
thereto.
^^ Previously filed as exhibits to the Company's Registration Statement on
Form S-1 (File No. 333-89166) and incorporated herein by reference
thereto.
^^^ Previously filed as exhibits to the Company's Annual Report on Form 10-K
for the year ended July 31, 2002 and incorporated herein by reference
thereto.
# Previously filed as exhibits to the Company's Annual Report on Form 10-KSB
for the year ended July 31, 1995 and incorporated herein by reference
thereto.
## Previously filed as exhibits to the Company's Registration Statement on
Form SB-2 (File No. 333-11575) and incorporated herein by reference
thereto.
### Previously filed as exhibits to the Company's Quarterly Report on Form
10-QSB for the quarter ended April 30, 1997 and incorporated herein by
reference thereto.
#### Previously filed as exhibits to the Company's Annual Report on Form 10-K
for the year ended July 31, 1999 and incorporated herein by reference
thereto.
##### Filed herewith.
(b) Reports on Form 8-K.
On February 4, 2003, we filed a report on Form 8-K which reported under
Item 5 thereof the resignation of Stanislaw M. Mikulski, M.D., F.A.C.P. as
Executive Vice President, Medical Director and member of the Board of Directors
of Alfacell, effective as of January 7, 2003 and the appointment of Dr. Paul
Weiss, Ph.D. to Alfacell's Board of Directors effective as of February 3, 2003.
- 15 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ALFACELL CORPORATION
(Registrant)
March 17, 2003 /s/ KUSLIMA SHOGEN
-------------------------------
Kuslima Shogen, Chief Executive
Officer, Acting Chief Financial
Officer (Principal Executive
Officer, Principal Accounting
Officer) and Chairman of the
Board
- 16 -
CERTIFICATIONS
I, Kuslima Shogen, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Alfacell Corporation;
2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;
3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and
c) presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent function):
a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and
b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.
Date: March 17, 2003
/s/ Kuslima Shogen
--------------------------------
Name: Kuslima Shogen
Title: Chief Executive Officer
and Chairman of the Board
- 17 -
CERTIFICATIONS
I, Kuslima Shogen, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Alfacell Corporation;
2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;
3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and
c) presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent function):
a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and
b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.
Date: March 17, 2003
/s/ Kuslima Shogen
-------------------------------
Name: Kuslima Shogen
Title: Acting Chief Financial
Officer
- 18 -